Johnson & Johnson Announces That TREMFYA Met Primary And Major Secondary Endpoints Demonstrating Both Improvement In Axial Symptoms And Reduction In Inflammation By MRI Assessment In The Phase 4 STAR Study Evaluating Biologic-Naïve Adults With Active Psoriatic Arthritis And Axial Involvement
STAR is the first and only dedicated randomized, double-blind, placebo-controlled study of its kind designed to prospectively evaluate an IL-23 inhibitor specifically in patients with axial involvement confirmed by
Johnson & Johnson's arthritis medicine TREMFYA worked well in a big study. When a company proves their medicine actually helps people, it suggests the business is moving forward.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.